Evolus

EOLS · NASDAQ

$7.37+$0.01 (+0.14%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.36

EOLS analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $15.30 (+107.6% upside)

Low: $12.12
Now: $7.37
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

EOLS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Aug 25, 2026	Maintains	Buy	$13.00	50%
BTIG	Jun 17, 2026	Maintains	Buy	$13.00	40%
BTIG	Mar 4, 2026	Maintains	Buy	$13.00	40%
HC Wainwright & Co.	Feb 3, 2026	Maintains	Buy	$20.00 → $13.00	50%
BTIG	Jan 22, 2026	Maintains	Buy	$18.00 → $13.00	40%
Stifel	Jan 13, 2026	Maintains	Buy	$20.00 → $17.00	45%
HC Wainwright & Co.	Jan 9, 2026	Maintains	Buy	$20.00	50%
Needham	Dec 24, 2025	Maintains	Hold	—	53%
Mizuho	Dec 2, 2025	Maintains	Outperform	$20.00 → $19.00	46%

The case for and against

Updated Oct 21, 2026

Bull case

Evolus is supported by resilient demand in the cash-pay aesthetic market, where management saw continued prioritization of treatments despite inflationary headwinds and raised 2026 revenue guidance to $327M-$337M, while Jeuveau’s 14% U.S. share provides a durable base. Growth is increasingly driven by Evolysse, with about 3,500 accounts, rising reorder rates, and accounts buying both Jeuveau and Evolysse generating 2.5x greater volume year-to-date, highlighting strong portfolio synergy and room for expansion as Sculpt nears FDA approval in 4Q26. The company has also delivered two consecutive quarters of positive adjusted EBITDA, and with approximately $50M of cash plus available debt capacity and a terminated ATM facility, it appears well positioned to fund product additions and move toward sustainable profitability.

Bear case

Evolus is exposed to a challenging competitive and execution backdrop, with risks from larger competitors, pricing pressure, and the possibility that Jeuveau and Evolysse fail to gain share as expected. The cited framework values the business off a 2035 discounted risk-adjusted revenue estimate of $215M, but that outlook is tempered by a 60% probability of success for Evolysse and the need to defend a commercial portfolio against supply chain disruption and potential tariffs. A deteriorating consumer spending environment, higher-than-expected operating expenses, regulatory delays, and possible dilution further weaken the fundamental case and support a negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.